Amura have two main platforms;
(1) AMcore™ which provides a powerful platform for the discovery of drugs with potential utility against a range of commercially attractive therapeutics targets.
Download the AMcore™ factsheet here
(2) ß-lactamase inhibitors. AM-112 is a lead candidate oxapenem ß-lactamase inhibitor (BLI) that exhibits substantially improved chemical stability within this otherwise labile class of compounds. AM-112 is an ideal combination partner for resistance susceptible ß-lactam antibiotics including: penicillins, cephalosporins and carbapenems to be used in first-line i.v. treatments for broad-spectrum hospital-acquired bacterial infections. Amura is seeking partners with a common vision towards progression and commercialisation of these combination therapeutics.
Download the ß-lactamase inhibitor (BLI) here